The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
p53, mdm2, EGFR, and msh2 expression in paired initial and recurrent glioblastoma multiforme
Open accessAbstract
BACKGROUND: The clinical course of glioblastoma multiforme is characterised by invasive growth and regular recurrence. Many genetic alteration have been identified in the genesis of the disease. However, information about immunohistochemical expression in recurrent lesions is sparse. OBJECTIVES: To determine (1) whether the p53/mdm2/EGFR/msh2 expression pattern differs in initial v recurrent glioblastoma multiforme; (2) whether a possible change in expression correlates with prognostic variables (progression-free survival time, total survival time); and (3) whether chemotherapy in addition to surgery and radiotherapy influences the p53/mdm2/EGFR/msh2 expression profile. METHODS: 27 patients were studied. They met the following criteria: histologically confirmed diagnosis of glioblastoma multiforme (WHO IV); total tumour resection at initial craniotomy; at least one re-craniotomy for glioblastoma multiforme recurrence; age 21 years or older. All underwent radiotherapy of at least 54 Gy, and 17 received additional chemotherapy. Immunohistochemical staining of initial tumours and recurrences was done with the following monoclonal antibodies: anti-p53 (DO-1), anti-mdm2 (IF-2), anti-EGFR (H11), and anti-msh2 (AB-1). RESULTS: In comparison with the initial tumour, recurrent lesions were characterised by reduced expression of p53 (p < 0.0001) and msh2 (p = 0.0012), while the numbers of mdm2 (p = 0.02), EGFR (p < 0.0001), and msh2 positive specimens (p < 0.0001) were reduced. Chemotherapy was associated with reduced msh2 expression (p < 0.0001). Immunohistochemical variables were not associated with patient survival. CONCLUSIONS: There are significant differences in the p53/mdm2/EGFR/msh2 expression patterns in initial v recurrent glioblastoma multiforme. There may be interactions between chemotherapy and changes in the msh2 expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TP53 expression has been compared in newly diagnosed patients and recurrent tumors with inconsistent results as to whether expression is altered upon recurrence [16,17,18].”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pathology and genetics of tumours of the nervous system.
Kleihues, P., & Cavennee, W. (2000) · International Agency for Research on Cancer eBooks · Cited by 1,432
Eukaryotic DNA mismatch repair
Kolodner, R. D., & Marsischky, G. T. (1999) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)80013-6 · Cited by 870
Primary and secondary glioblastomas: From concept to clinical diagnosis
Kleihues, P., & Ohgaki, H. (1999) · Neuro-Oncology · doi:10.1093/neuonc/1.1.44 · Cited by 586
Friedman, H. S., McLendon, R. E., Kerby, T., Dugan, M., Bigner, S. H., Henry, A. J., Ashley, D. M., Krischer, J., Lovell, S., Rasheed, K., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.12.3851 · Cited by 423
Activation and activities of the p53 tumour suppressor protein
Bálint, É., & Vousden, K. H. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2128 · Cited by 313
The p53 and Mdm2 families in cancer
Michael, D. (2002) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(01)00264-7 · Cited by 284
Simmons, M. L., Lamborn, K. R., Takahashi, M., Chen, P.-Y., Israel, M. A., Berger, M. S., Godfrey, T. E., Nigro, J. M., Prados, M. D., Chang, S. M., et al. (2001) · PubMed · Cited by 278
Molecular pathways in the formation of gliomas
von Deimling, A., Louis, D. N., & Wiestler, O. D. (1995) · Glia · doi:10.1002/glia.440150312 · Cited by 245
Amplification of Epidermal Growth Factor Receptor Gene in Gliomas: Histopathology and Prognosis
Hurt, M. R., Moossy, J., Donovan-Peluso, M., & Locker, J. (1992) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199201000-00010 · Cited by 197
Pathology and Genetics of Tumours of the Nervous System
McComb, R. D. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.8.749-a · Cited by 190
Research works printed but not linked: 1
- Scherer HJ. Cerebral astrocytomas and their derivatives. Am J Cancer 1940;40:159-98.
Cited by
The p53 Pathway in Glioblastoma
Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., Setiady, I., Deveau, C., Saoud, K., et al. (2018) · Cancers · doi:10.3390/cancers10090297 · Cited by 440
Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma
DeCordova, S., Shastri, A., Tsolaki, A. G., Yasmin, H., Klein, L., Singh, S. K., & Kishore, U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01402 · Cited by 346
A comprehensive profile of recurrent glioblastoma
Campos, B., Olsen, L. R., Urup, T., & Poulsen, H. S. (2016) · Oncogene · doi:10.1038/onc.2016.85 · Cited by 248
Gene Therapy and Targeted Toxins for Glioma
King, G. D., Curtin, J. F., Candolfi, M., Kroeger, K. M., Lowenstein, P. R., & Castro, M. G. (2005) · Current Gene Therapy · doi:10.2174/156652305774964631 · Cited by 116
Maru, S., Holloway, K., Flynn, G., Lancashire, C. L., Loughlin, J., Male, D. K., & Romero, I. A. (2008) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2008.04.029 · Cited by 121
Metadata
- Authors
- Stark, A. M.
- Affiliations
- Christian-Albrechts-Universität zu Kiel (DE)
- Corresponding author
- Stark, A M
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 2003-06-01
- Volume
- 74
- Issue
- 6
- Pages
- 779-783
- ISSN
- 0022-3050 (ISSN-L)
- PMC
- PMC1738476
- OpenAlex
- W2123847172
- Cited by
- 51
- References
- 27
- Citations by year
- 2024: 2 · 2023: 1 · 2022: 1 · 2021: 3 · 2020: 4 · 2019: 3 · 2018: 3 · 2017: 3 · 2016: 3 · 2014: 2 · 2013: 5
- FWCI
- 0.93
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Neurology Neurosurgery & Psychiatry (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Keywords
- glioblastoma, recurrent glioblastoma, p53, MDM2, EGFR, MSH2, tumor recurrence, chemotherapy, progression-free survival, survival, tumor suppressor, DNA mismatch repair
- MeSH terms
- Adult, Aged, Antibodies, Monoclonal, Antibodies, Neoplasm, Brain Neoplasms, DNA-Binding Proteins, Female, Glioblastoma, Humans, Immunohistochemistry, Male, Middle Aged, Neoplasm Invasiveness, Neoplasm Recurrence, Local, Nuclear Proteins, Proto-Oncogene Proteins, Genes, p53, Genes, erbB-1, MutS Homolog 2 Protein, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: p53, mdm2, EGFR, and msh2 expression in paired initial and recurrent glioblastoma multiforme. https://app.cochat.ai/papers/10.1136/jnnp.74.6.779
- The paper
- Stark, A. M. (2003). p53, mdm2, EGFR, and msh2 expression in paired initial and recurrent glioblastoma multiforme. Journal of Neurology, Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.74.6.779
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
